Colin Gillis

Colin Gillis is Senior Vice President and CFO, IMP Group International Inc. 

  • AdobeStock_59790119
    CPD Supplement

    The Olaratumab experience

    2022-06-09T10:47:00

    As highlighted within this CPD article, a conditional marketing authorisation (CMA) can be revoked in Europe. However only one occurrence has occurred since 2006 (in April 2019). Lartruvo (olaratumab), a humanised antibody, was granted a CMA via accelerated assessment on 9 November 2016 for adult patients with a locally advanced, ...

  • AdobeStock_268793304
    Journal

    Gene therapy: regional assessment comparison

    2020-11-01T15:52:00

    Axicabtagene ciloleucel (tradename YESCARTA) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets CD19 and is approved for the treatment of aggressive, relapsed or refractory forms of B-cell non-Hodgkins lymphoma (NHL). The active substance is composed of a patient’s cells that have undergone ex vivo modification, which causes ...

  • AdobeStock_268793304
    Journal

    Global regulatory frameworks for the development of gene therapy products

    2020-11-01T15:44:00

    Gene therapies have the potential to revolutionise the global healthcare system. Some of these products may offer curative benefits to patients with devastating conditions. This continuing professional development (CPD) supplement provides an overview of the regulatory framework for the development of gene therapy products in key markets.

  • AdobeStock_59790119
    CPD Supplement

    Expedited drug development regulatory pathways in the EU and the US

    2020-10-01T09:54:00

    This continuing professional development (CPD) supplement focuses on the regulatory framework available to drug developers for expediting their products’ development and review processes in the EU and US. These mechanisms are relevant for products which address an unmet medical need in the treatment of a serious and/or life-threatening condition.